retatrutide clinical trial results 2024 2025 press release produces up to 30.3% weight loss in Phase 3 Lilly's triple agonist, retatrutide, demonstrated
Description
gallbladder complications
Although Lilly and Novo currently dominate the approved market, limiting compounding would make it easier for new entrants to compete without facing compounded competition
Patients often ask whether their insurance, such as Aetna, will cover it
Patients should be counseled on strategies to minimize these effects, including eating smaller meals, avoiding high-fat foods, and maintaining adequate hydration
HbA1c decreased from 5.7% to 4.9%
Others are where they crave
